Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments
- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth attracted over 500 visitors. - Educated over 300 Thai physicians on the innovative "Nabolift" technique through the "Nabota Master Class (NMC)." - Established its position as a premium global brand...
Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment
MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest phar...
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant ste...
Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results
SEOUL, South Korea, May 14, 2024 /PRNewswire/ -- CGBio, a leading medical device company, announced a significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes, "Novosis" and "Excelos Inject," which have been published in the '...
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority ofBrazil, ANVISA. Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and ...
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill
SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm
Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome
Hair Fill. HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive
technology for scalp rejuvenation and hair growth.
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines
'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines... The first case of overseas launch SEOUL, South Korea, Aug. 16, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that 'Fuxuprazan' is officially launched i...
Maypharm Launches SEDY FILL, a hyaluronic acid body filler
SEOUL, South Korea and NEW YORK, Aug. 9, 2023 /PRNewswire/ -- Maypharm has launchedSEDY FILL, a hyaluronic acid body filler maximized in effect to guarantee customer satisfaction.SEDY FILL is an injectable dermal filler designed for non-surgical correction of body shape. The uniqueness of its pr...
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs
– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial inChina aiming to reach 100 countries by 2027" SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for t...
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet
SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio. Daewoong Pharmaceutical (Jeon Sen...
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine
* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023
- New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing erosive esophagitis (EE) regardless of food intake, and in a Chinese pivotal clinical trial program for the treatment of EE SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ -- Daewoong Pharm...
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal
SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged. On April 4, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Chang-jae Lee) announced that the efficacy and safety evalu...
Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration
- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceuti...
Maypharm's Hyalmass filler with Hybrid Technology obtained CE to hit Europe and America's market
SEOUL, South Korea and NEW YORK, April 18, 2023 /PRNewswire/ -- Being already popular onSouth Asia market, particularly in Vietnam, Philippines, Thailand, China, for Hybrid Technology and highly dense HA for long-lasting effect, Hyalmass filler obtains CE to properly enterEurope, America etc mark...
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries
* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil and Mexico in last February * Aiming to enter 50 countries by 2030 SEOUL, South Korea, March 22, 2023 /PRNewswire/ -- Daewoong Pharmaceutical began the advance into the global market in full swin...
Maypharm CO, LTD., launched a new CE filler: Multi-layered Phasic Hyaluronic Acid with lidocaine and CE approved MayFill Filler
SEOUL, South Korea and NEW YORK, Feb. 20, 2023 /PRNewswire/ -- Maypharm, a brand holder of such popular products as Metoo fill, Sedy fill, Metox, Mennus, Hairna, Eyebella, has been busy with developing new products in Aestheticians market. Metoo Fill is the first CE approved filler made by Maypha...
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
